Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis

Science Translational Medicine

Volumn 6, Issue 234, 2014, Pages

  Das, Shantanabha ^a   Freier, Anja ^b   Boussoffara, Thouraya ^c   Das, Sushmita ^d   Oswald, Detlef ^e   Losch, Florian O ^b   Selka, Melanie ^b   Sacerdoti Sierra, Nina ^f   Schönian, Gabriele ^b   Wiesmüller, Karl Heinz ^g   Seifert, Karin ^h   Schroff, Matthias ^e   Juhls, Christiane ^e   Jaffe, Charles L ^f   Roy, Syamal ^a   Das, Pradeep ^d   Louzir, Hechmi ^c   Croft, Simon L ^h   Modabber, Farrokh ⁱ   Walden, Peter ^b  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^d INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^e MOLOGEN AG   (Germany)

^f HEBREW UNIVERSITY   (Israel)

^g EMC MICROCOLLECTIONS GMBH   (Germany)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; LEISHMANIA VACCINE; TUMOR NECROSIS FACTOR ALPHA; EPITOPE; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA IMMUNIZATION; DNA SEQUENCE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG SYNTHESIS; FEMALE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LEISHMANIA DONOVANI; LEISHMANIASIS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; METABOLISM;

ANIMALS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; INTERLEUKIN-2; LEISHMANIASIS; MICE; MICE, INBRED BALB C; VACCINES, DNA;

EID: 84899792392     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008222     Document Type: Article

References (36)

1. J. Alvar, I. D. Vélez, C. Bern, M. Herrero, P. Desjeux, J. Cano, J. Jannin, M. den Boer; WHO Leishmaniasis Control Team, Leishmaniasis worldwide and global estimates of its incidence. PLOS One 7, e35671 (2012).
2. P. Kaye, P. Scott, Leishmaniasis: Complexity at the host-pathogen interface. Nat. Rev. Microbiol. 9, 604-615 (2011).
3. S. L. Croft, P. Olliaro, Leishmaniasis chemotherapy - Challenges and opportunities. Clin. Microbiol. Infect. 17, 1478-1483 (2011).
4. L. Stockdale, R. Newton, A review of preventative methods against human leishmaniasis infection. PLOS Negl. Trop. Dis. 7, e2278 (2013).
5. C. B. Palatnik-de-Sousa, Vaccines for canine leishmaniasis. Front. Immunol. 3, 69 (2012).
6. A. C. Stanley, C. R. Engwerda, Balancing immunity and pathology in visceral leishmaniasis. Immunol. Cell Biol. 85, 138-147 (2007).
7. K. J. Evans, L. Kedzierski, Development of vaccines against visceral leishmaniasis. J. Trop. Med. 2012, 892817 (2012).
8. B. Ostyn, K. Gidwani, B. Khanal, A. Picado, F. Chappuis, S. P. Singh, S. Rijal, S. Sundar, M. Boelaert, Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: A prospective study. PLOS Negl. Trop. Dis. 5, e1284 (2011).
9. A. Khamesipour, Y. Dowlati, A. Asilian, R. Hashemi-Fesharki, A. Javadi, S. Noazin, F. Modabber, Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23, 3642-3648 (2005).
10. K. S. Tabbara, N. C. Peters, F. Afrin, S. Mendez, S. Bertholet, Y. Belkaid, D. L. Sacks, Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect. Immun. 73, 4714-4722 (2012).
11. Working Group on Research Priorities for Development of Leishmaniasis Vaccines, C. H. Costa, N. C. Peters, S. R. Maruyama, E. C. de Brito Jr., I. K. Santos, Vaccines for the leishmaniases: Proposals for a research agenda. PLOS Negl. Trop. Dis. 5, e943 (2011).
12. P. M. Kaye, T. Aebischer, Visceral leishmaniasis: Immunology and prospects for a vaccine. Clin. Microbiol. Infect. 17, 1462-1470 (2011).
13. J. Chakravarty, S. Kumar, S. Trivedi, V. K. Rai, A. Singh, J. A. Ashman, E. M. Laughlin, R. N. Coler, S. J. Kahn, A. M. Beckmann, K. D. Cowgill, S. G. Reed, S. Sundar, F. M. Piazza, A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29, 3531-3537 (2011).
14. M. S. Duthie, V. S. Raman, F. M. Piazza, S. G. Reed, The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine 30, 134-141 (2012).
15. A. Maroof, N. Brown, B. Smith, M. R. Hodgkinson, A. Maxwell, F. O. Losch, U. Fritz, P. Walden, C. N. Lacey, D. F. Smith, T. Aebischer, P. M. Kaye, Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J. Infect. Dis. 205, 853-863 (2012).
16. J. S. Blum, P. A. Wearsch, P. Cresswell, Pathways of antigen processing. Annu. Rev. Immunol. 31, 443-473 (2013).
17. F. Zepp, Principles of vaccine design - Lessons from nature. Vaccine 28 (Suppl. 3), C14-C24 (2010).
18. M. A. Kutzler, D. B. Weiner, DNA vaccines: Ready for prime time? Nat. Rev. Genet. 9, 776-788 (2008).
19. F. Faurez, D. Dory, V. Le Moigne, R. Gravier, A. Jestin, Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine 28, 3888-3895 (2010).
20. L. López-Fuertes, E. Pérez-Jiménez, A. J. Vila-Coro, F. Sack, S. Moreno, S. A. Konig, C. Junghans, B. Wittig, M. Timón, M. Esteban, DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 21, 247-257 (2002).
21. R. Basu, S. Roy, P. Walden, HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 195, 1373-1380 (2007).
22. S. Bhaumik, R. Basu, S. Sen, K. Naskar, S. Roy, KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27, 1306-1316 (2009).
23. S. Rafati, F. Zahedifard, F. Nazgouee, Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24, 2169-2175 (2006).
24. M. Chenik, S. Lakhal, N. Ben Khalef, L. Zribi, H. Louzir, K. Dellagi, Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites. Parasitology 132, 493-509 (2006).
25. A. Ghosh, W. W. Zhang, G. Matlashewski, Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20, 59-66 (2001).
26. R. L. Coffman, D. A. Lebman, P. Rothman, Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54, 229-270 (1993).
27. H. W. Murray, G. D. Miralles, M. Y. Stoeckle, D. F. McDermott, Role and effect of IL-2 in experimental visceral leishmaniasis. J. Immunol. 151, 929-938 (1993).
28. F. Y. Liew, Y. Li, S. Millott, Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145, 4306-4310 (1990).
29. O. Finco, R. Rappuoli, Designing vaccines for the twenty-first century society. Front. Immunol. 5, 1-6 (2014).
30. E. M. Carvalho, A. Barral, D. Pedral-Sampaio, M. Barral-Netto, R. Badaró, H. Rocha, W. D. Johnson Jr., Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J. Infect. Dis. 165, 535-540 (1992).
31. E. M. Carvalho, O. Bacellar, C. Brownell, T. Regis, R. L. Coffman, S. G. Reed, Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152, 5949-5956 (1994).
32. S. Noazin, F. Modabber, A. Khamesipour, P. G. Smith, L. H. Moulton, K. Nasseri, I. Sharifi, E. A. Khalil, I. D. Bernal, C. M. Antunes, M. P. Kieny, M. Tanner, First generation leishmaniasis vaccines: A review of field efficacy trials. Vaccine 26, 6759-6767 (2008).
33. A. Selvapandiyan, R. Dey, S. Gannavaram, I. Lakhal-Naouar, R. Duncan, P. Salotra, H. L. Nakhasi, Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J. Trop. Med. 2012, 631460 (2012).
34. B. Ferraro, M. P. Morrow, N. A. Hutnick, T. H. Shin, C. E. Lucke, D. B. Weiner, Clinical applications of DNA vaccines: Current progress. Clin. Infect. Dis. 53, 296-302 (2011).
35. A. Sassi, H. Louzir, A. Ben Salah, M. Mokni, A. Ben Osman, K. Dellagi, Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin. Exp. Immunol. 116, 127-132 (1999).
36. D. J. Bradley, J. Kirkley, Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30, 119-129 (1977).